{"nct_id":"NCT04082364","title":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","status":"COMPLETED","status_verified_date":"2025-05","start_date":"2019-09-30","start_date_type":"ACTUAL","primary_completion_date":"2024-01-15","primary_completion_date_type":"ACTUAL","completion_date":"2025-03-25","completion_date_type":"ACTUAL","phases":["PHASE2","PHASE3"],"tickers":["MGNX"]}